Benzinga

Benzinga

Benzinga

lunes, septiembre 07

Guardant Health Inc

GHNASDAQ
Trade with Public
Trade with Public
$161.41
0.370.23%
al cierre: Sep 4, 5:00 PM EST
$162.90
1.490.92%
After hour: Sep 4, 6:42 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Guardant Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for Guardant Health (GH).

Price Target Range — 7 Quarters

Analyst Consensus — 24 Analysts

24Buy
Consensus RatingBuy# Analysts24Avg. Consensus PT$158Upside to Avg. PT-3.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 2, 2026BTIGMark MassaroMaintainedBuy$195
Aug 4, 2026Piper SandlerDavid WestenbergPT RaiseOverweight$135→$193
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BTIG Reiterates Buy on Guardant Health, Maintains $195 Price Target

BTIG analyst Mark Massaro reiterates Guardant Health (NASDAQ:GH) with a Buy and maintains $195 price target.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Guardant Health, Raises Price Target to $193

Piper Sandler analyst David Westenberg maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $135 to $193.
Benzinga Newsdesk

PRO
Stephens & Co. Maintains Overweight on Guardant Health, Raises Price Target to $195

Stephens & Co. analyst Mason Carrico maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $170 to $195.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $185

Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $175 to $185.
Benzinga Newsdesk

PRO
Stifel Maintains Buy on Guardant Health, Raises Price Target to $180

Stifel analyst Daniel Arias maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $130 to $180.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Guardant Health, Raises Price Target to $200

RBC Capital analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Outperform and raises the price target from $185 to $200.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved